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Abstract: Personalized medicine, with the aim of safely, effectively, and cost-effectively 
targeting treatment to a prespecified patient population, has always been a long-time goal within 
health care. It is often argued that personalizing treatment will inevitably improve clinical 
outcomes for patients and help achieve more effective use of health care  resources. Demand 
is increasing for demonstrable evidence of clinical and cost-effectiveness to support the use of 
personalized medicine in health care. This paper begins with an overview of the existing chal-
lenges in conducting economic evaluations of genetics- and genomics-targeted technologies, 
as an example of personalized medicine. Our paper illustrates the complexity of the challenges 
faced by these technologies by highlighting the variations in the issues faced by diagnostic tests 
for somatic variations, generally referring to genetic variation in a tumor, and germline varia-
tions, generally referring to inherited genetic variation in enzymes involved in drug metabolic 
pathways. These tests are typically aimed at stratifying patient populations into subgroups on 
the basis of clinical effectiveness (response) or safety (avoidance of adverse events). The paper 
summarizes the data requirements for economic evaluations of genetics and genomics-based 
technologies while outlining that the main challenges relating to data requirements revolve 
around the availability and quality of existing data. We conclude by discussing current devel-
opments aimed to address the challenges of assessing the cost-effectiveness of genetics and 
genomics-based technologies, which revolve around two central issues that are interlinked: the 
need to adapt available evaluation methods and identifying who is responsible for generating 
evidence for these technologies.
Keywords: pharmacogenetics, pharmacogenomics, cost-effectiveness, economic evaluation, 
somatic variations, germline variations
Introduction
Personalized medicine, with the aim of safely, effectively, and cost-effectively targeting 
treatment to a prespecified patient population, has always been a long-time goal within 
health care. While there are many definitions of the term, the concept of personalized 
medicine revolves around a central theme relating to the use of combined knowledge 
(genetics or otherwise) to predict disease susceptibility, disease prognosis, or treatment 
response of a person to improve the person’s health.1 Progress made in the development 
of personalized medicine in recent decades has coincided with health care  systems 
placing greater emphasis on evidence-based clinical practice, particularly as they are 
operating within an increasingly budget-scarce environment. It is often argued that 
personalizing treatment will inevitably improve clinical outcomes for patients and help 
achieve more effective use of health care  resources. Hence, demand is increasing for 
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demonstrable evidence of clinical and cost-effectiveness to 
support the use of personalized medicine in health care.
It is increasingly recognized that there is a need to apply 
the principles and framework of economic evaluation to con-
duct a comparative analysis of both the costs and outcomes 
of technologies used to personalize medicine, with the aim 
of providing sufficiently robust evidence2,3 for decision-
makers entrusted with allocating health care  budgets.4,5 The 
demand for such evidence by health care  decision-makers 
has led to widespread publication of economic evaluations 
of health care  technologies in numerous academic journals 
of assorted medical specialties, including a number of the 
journals focusing on genetics- and genomics-based technolo-
gies used to target medicines. Several systematic reviews 
of economic evaluations of technologies used to personal-
ize medicine are summarized in Table 1. The economic 
evaluations identified by these reviews found that many of 
the technologies assessed were cost-effective, with very 
few being cost-saving. All reviews highlighted the need to 
improve the quality of the evidence base, particularly the cost 
and outcome data used to populate economic evaluations. 
Nevertheless, the focus of the two most recent reviews6,7 on 
economic evaluations that utilized quality adjusted life years 
(QALYs), the preferred outcome for economic evaluations 
in several jurisdictions,8,9 suggested that the quality of the 
evidence base may be improving.
In this paper, we aim to present an overview of the existing 
challenges and current developments in conducting economic 
evaluations of genetics- and genomics-targeted technolo-
gies (hereafter called pharmacogenetic technologies) as an 
example of personalized medicine. Several recent reviews 
have explored different aspects of the challenges affecting 
the evaluation of pharmacogenetics. Phillips et al14 presented 
a detailed overview of various aspects relating to economic 
evaluations of personalized medicine, and highlighted six areas 
for future research, ranging from applying existing methods 
to assessments of personalized medicine to developments of 
new conceptual frameworks and methods specific to these 
technologies. Godman et al15 discussed current knowledge of 
the value of personalized medicine and concerns relating to 
personalized medicine from a payer’s perspective. Annemans 
et al16 and Buchanan et al17 separately explored methodological 
challenges of conducting economic evaluations of genomic 
interventions, and discussed possible solutions to some of 
these issues. Our paper takes another approach in illustrating 
the complexity of the challenges faced by pharmacogenetics 
by highlighting the variations in the issues faced by genetics- 
and genomics-based companion diagnostic tests for somatic 
variations, generally referring to genetic variation in a tumor, 
and germline variations, generally referring to inherited genetic 
variation in enzymes involved in drug metabolic pathways. 
Such tests are typically aimed at stratifying patient populations 
Table 1 Systematic reviews of economic evaluations of genetics- and genomics-based technologies
Author 
(year)
Date  
searched
Focus of systematic review Total studies 
identified
PGx studies 
identified
Quality assessment conducted
Hatz et al  
(2014)7
1950 to  
February 2013
economic evaluations of genetic  
health technologies that used  
LYG or QALY as outcomes
84 studies Not reported Stringent inclusion criteria based on 
adherence to an economic evaluation 
checklist
Phillips and  
van Bebber  
(2004)10
1950 to July  
2004
Cost-effectiveness analyses of  
pharmacogenomic interventions
11 studies 11 studies Assessment of studies’ quality by stringent 
inclusion criteria and clear description of 
studies 
Identification of key drivers of cost-
effectiveness and future research priorities
Phillips et al  
(2014)6
1976–2011 economic evaluations of genetic  
health technologies that are  
available or soon to be available  
that used QALY as the outcome
59 studies Not reported inclusion criteria based on studies being 
listed in a systematically compiled registry 
of published economic evaluations
vegter et al  
(2010)11
2000 to July  
2010
economic evaluations of  
pharmacogenetic and genomic  
screening programs
42 studies 42 studies Discussion of contents of reviewed 
studies and adherence to key aspects of 
pharmacoeconomic guidelines
vegter et al  
(2008)12
2000 to  
December 2007
economic evaluations of  
pharmacogenetic and genomic  
screening programs
20 studies 20 studies Discussion of contents of reviewed studies 
and adherence to pharmacoeconomic 
guidelines
wong et al  
(2010)13
1950 to  
October 2009
economic evaluations of  
pharmacogenetic interventions
34 studies 34 studies Assessment of quality of reviewed studies 
using a published quantitative grading 
system
Abbreviations: LYG, life years gained; PGx, pharmacogenetic; QALY, quality adjusted life year.
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into subgroups on the basis of clinical effectiveness (response) 
or safety (avoidance of adverse events). Our paper places par-
ticular emphasis on technologies used to prevent adverse drug 
events as they are seldom considered in the literature.18
Pharmacogenetic technologies
Pharmacogenetic technologies can be broadly split into two 
types of tests with each type using a companion diagnostic to 
either identify: 1) somatic variations of a disease, for example 
tumors, or 2) germline variations in individuals, for example, 
drug metabolizing enzymes. Some examples of companion 
genetics-based diagnostics currently available for use in 
practice are tabulated in Table 2. As these examples show, 
companion diagnostics used to identify somatic variations are 
generally used to target treatment in terms of clinical response 
and companion diagnostics used to identify germline varia-
tions commonly target medicines administered to specific 
populations with the aim of minimizing adverse events.
Challenges for economic 
evaluations of pharmacogenetics
The introduction and use of economic evaluations in 
health care  decision-making historically centered on 
the assessment of medicines.20 The source of data for an 
 economic evaluation typically comes from either a single trial 
or a multitude of sources combined within a model-based 
economic evaluation. A trial-based economic evaluation 
incorporates data collection of clinical effectiveness, health 
status, and resource use data into the clinical trial protocol, 
with the data collected from the trial population. A model-
based economic evaluation is based on a systematic compi-
lation of data from many different sources within a single 
framework, such as evidence of clinical effectiveness, utility 
and cost data from the literature, practice-based data sources 
(such as audits and observational studies), and expert opinion. 
The “gold standard” for the compilation of data for economic 
models is via systematic reviews of published evidence.21 
While the basic framework for economic evaluations of 
pharmacogenetic technologies is similar to medicines, some 
specific issues and challenges can be identified and assessed 
based on economic evaluation checklists.9,22
Defining the study question
An economic evaluation is defined by the study question 
and the distinct scope of the study. This aspect incorporates 
the need to clearly describe every characteristic of the 
intervention being assessed, including descriptions of the 
intervention, the role and place of the intervention within 
clinical pathways, the target patient population and the 
comparator(s). Defining the precise nature of a pharmacoge-
netic technology can be particularly problematic as the test 
is not the intervention by itself. Instead, the test is a tool to 
assist decision-making with regard to future health care, with 
future clinical pathways largely depending on the results from 
the test. Testing for a genetic variation of interest can often 
be conducted using a variety of genotyping methods, with 
each method having different test characteristics such as test 
sensitivity, specificity, reproducibility, and precision.23,24 For 
example, CYP2D6 genotyping can be conducted using a large 
number of different assays, many of which can be in-house 
laboratory tests and measuring assorted CYP2D6 variations. 
This ambiguity as to the exact nature of the intervention 
(and crucially, therefore, convincing clinical evidence for 
“the intervention”) actually resulted in a planned economic 
evaluation being precluded from a health technology assess-
ment of CYP2D6 pharmacogenetic testing.25
establishing clinical pathways
Identifying the place of a pharmacogenetic test within care 
pathways is crucial, not only to guide the selection of a 
relevant comparator (which is usually current standard care 
Table 2 Selected examples of genetics-based companion diagnostics
Companion diagnostic Purpose
Testing for somatic variations
 ALK test To predict response to crizotinib therapy
 eGFR test To predict response to erlotinib, gefitinib, 
or afatinib therapy
 HeR2 test To predict response to trastuzumab or 
lapatinib therapy
Testing for germ line genetic variations
 CYP2C9 test To predict the safety and efficacy of 
warfarin therapy
 CYP2C19 test To predict the safety and efficacy of patients 
on clopidogrel
 CYP2D6 test To predict the safety and efficacy of codeine 
therapy
 HLA-B*1502 test To predict the safety of carbamazepine 
therapy based on the risk of hypersensitivity
 HLA-B*5701 test To predict the safety of abacavir therapy 
based on the risk of hypersensitivity
 TPMT test To predict the safety of azathioprine 
therapy based on the risk of neutropenia
 UGT1A1 test To predict the safety of irinotecan 
chemotherapy based on the risk of 
neutropenia
Note: Data from US Food and Drug Administration (2014).19
Abbreviations: ALK, anaplastic lymphoma kinase; CYP, cytochrome P450; 
eGFR, epidermal growth factor receptor; HeR2, human epidermal growth factor 
receptor 2; HLA-B, human leukocyte antigen; TPMT, thiopurine methyltransferase; 
UGT, uridine diphospho glucuronosyltransferase.
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in economic evaluations conducted for health technology 
assessments), but also to guide the use of the companion drug 
and subsequent treatment pathways to be modeled. Human 
epidermal growth factor receptor 2 (HER2) testing presents 
a good example of this. HER2 testing was first developed to 
assist in the targeting of trastuzumab.26 When first introduced, 
HER2 testing was conducted only in the metastatic setting27 
as clinical evidence only supported the use of trastuzumab 
in patients with metastatic breast cancer. Testing is now con-
ducted in patients with early stage breast cancer due to the 
emergence of evidence supporting the use of trastuzumab in 
both adjuvant and metastatic settings.26,28,29 The exact place 
along the treatment pathway where testing occurs may change 
the cost-effectiveness of the intervention because of differ-
ences in the type of treatment subsequently received and the 
costs and outcomes arising from these.
Somatic versus germline testing
HER2 testing is an example of a somatic test. The challenges 
for establishing an evidence base are arguably greater for 
germline tests than somatic tests, particularly when germline 
polymorphisms simultaneously affect the metabolism of 
various drugs for different diseases; CYP2D6 is one such 
example. Pharmacogenetic profiles obtained from CYP2D6 
tests can be used in multiple patient populations to inform 
prescribing of various medications for a range of clinical 
indications.30,31 An economic evaluation needs to be con-
ducted to assess the cost-effectiveness of each specific use 
of CYP2D6 testing in each specific patient population. The 
defined scope of an economic evaluation will not consider the 
added costs and potential benefits that may be incurred from 
CYP2D6 testing for all other indications that can potentially 
occur in an individual’s lifetime. It can be argued that one 
advantage of a test that affects several conditions is that the 
test need be conducted only once over an individual’s lifetime. 
However, this fails to consider that tests evolve over time and 
that clinically important polymorphisms may only become 
apparent over time, requiring additional, more accurate, 
genotyping in the future. As tests become more sophisticated 
so as to be able to concurrently test for multiple genetic 
polymorphisms,16 defining the study question will become 
much more complicated, particularly for pharmacogenetic 
tests of germline polymorphisms.
Data requirements for an  
economic evaluation
Key data needed for an economic evaluation of a pharmaco-
genetic test include outcome data on the clinical effectiveness 
and utility of the technology, changes in health status as 
well as resource use and related costs of the affected patient 
population and the uptake of the test. Fundamentally, the 
challenges relating to the data requirements for the economic 
analysis of a pharmacogenetic intervention revolve around 
the availability and quality of existing data.
There is also a need to consider the current lack of 
agreement on the appropriate methods and parameters to be 
used when including adverse events in an economic model32 
which leaves analysts to decide by themselves on which 
adverse event parameters to include, with key options being 
cost, utility, and clinical parameters. These variations in 
economic modeling practice can directly affect the  relative 
cost- effectiveness of pharmacogenetic technologies that aim 
to reduce adverse events, where the incremental gains in 
outcomes are based on reducing adverse events by stratify-
ing patients into subgroups based on their predicted risk. 
There is a growing need to standardize how adverse event 
parameters are incorporated in economic models. The main 
parameters that should be considered for standard inclusion 
are the frequency of adverse events and their clinical impact 
on patient outcomes, changes in health status, resource use, 
and downstream costs due to the adverse events and subse-
quent changes in clinical pathways.33 Exempting any of these 
parameters may significantly affect the findings of an eco-
nomic evaluation, which may subsequently limit the relevance 
of the analysis for use in health care  decision-making.
Clinical effectiveness
There are currently few prospective studies conducted of 
pharmacogenetics10,11,13 and this paucity has had a large 
impact on the quality of evidence available to support the 
use of pharmacogenetics in clinical practice. To understand 
the reasons for the scarcity of prospective pharmacogenetic 
studies, it is essential to acknowledge the challenges that 
are inherent to assessing any health care  intervention that 
relies on stratifying patients into treatment subgroups. Any 
study involving multiple subgroups needs a sufficiently large 
sample size to demonstrate significant differences in patient 
outcomes.34 Conducting multicenter and multinational studies 
is one potential solution to ensure a trial has sufficient power 
to show statistically significant differences in patient outcomes 
but the cost of such studies may be prohibitively high.
These challenges are often more overwhelming when 
evaluating pharmacogenetics that aim to reduce adverse 
events compared to those that predict response. A part of the 
issue relates to the number of subgroups that patients need 
to be stratified into. Tests for somatic variations that predict 
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response often only need to stratify patients into two groups, 
consisting of responders and non-responders, usually based 
on the presence of the polymorphism of interest that predicts 
the susceptibility of the disease to the companion drug. On 
the other hand, tests for germline variations to predict adverse 
events often first require evidence linking genotype to phe-
notype, which subsequently inform patient stratification and 
the number of relevant subgroups involved that are usually 
determined by findings from observational cohort studies 
linking pharmacogenetic variations and patient outcomes.35–37 
The challenges encountered while assessing pharmacogenet-
ics that predict adverse events are also linked to the frequency 
at which the adverse event of interest occurs.34 While response 
(or the lack of it) can be measured in every patient, certain 
adverse events only affect a certain proportion of patients 
within a study, thus emphasizing the need for studies with 
large sample sizes.
Ideally, the clinical outcomes of effectiveness should be 
real clinical end-points instead of surrogate or intermediate 
outcomes.38 However, particularly in pharmacogenetics, sur-
rogate outcomes may be more common.39 To illustrate this 
challenge, consider the examples of TPMT and UGT1A1 
testing, for which the clinical adverse event of interest is 
neutropenia represented by hematological laboratory find-
ings and an increased risk of infection. While neutropenia 
predisposes patients to severe and potentially fatal infection, 
it has no clinical implication on health status unless it is 
accompanied by an infection or a clinical sequelae40 and can 
be classified as a surrogate outcome with clinically relevant 
events such as febrile and septic neutropenia being the actual 
clinical outcomes. When surrogate outcomes are used, further 
evidence on the association between the surrogate outcomes 
and the real clinical end-points of particular relevance to the 
patient population should be presented to describe the true 
value of the intervention.41,42 However, there are scarce data 
on the actual proportion of neutropenic patients who develop 
febrile or septic neutropenia in clinical practice43 and assump-
tions made on the estimated proportion may subsequently 
weaken the evidence base needed for robust assessment of 
the cost-effectiveness of TPMT and UGT1A1 tests.37,43
Clinical utility
Challenges faced while determining the clinical utility of 
a companion diagnostic44 are underpinned by the need to 
show evidence that patient outcomes are improved by  testing. 
This relies heavily on the pharmacogenetics-guided treat-
ment options that are available once information from a 
pharmacogenetic test is available to inform prescribing deci-
sions.45 Treatment options for a test that predicts response 
depend mainly on the alternative treatments available to 
nonresponders while that for a test reducing adverse events 
depends primarily on the availability of either an alterna-
tive treatment strategy (such as in the case of abacavir and 
HLA-B*5701 testing) or a pharmacogenetics-based dosing 
algorithm and evidence linking the alternative dosing strat-
egy with patient outcomes (such as in the case of warfarin 
and CYP2C9 and VKORC1 tests).35,36
Pharmacogenetics-based dosing algorithms are currently 
poorly developed. The demand for guidance to utilize phar-
macogenetics data in decision-making within clinical practice 
has led to the development of several pharmacogenetics-based 
dosing algorithms for warfarin based on the therapeutic range 
of a drug (a surrogate or intermediate outcome). Clinical data 
primarily based on various observational studies and some 
small prospective studies have supported the potential clinical 
utility of the genotype-guided dosing recommendations.46–49 
However, recently published results of two randomized 
clinical trials of pharmacogenetics-based dosing of warfarin 
came to divergent conclusions.35,36 Recommendations for 
genotype-guided dosing that are not supported by robust 
evidence and which may later be contradicted by results from 
well-designed randomized controlled trials may discourage 
the use of pharmacogenetics within clinical practice and 
subsequently impair the development of the evidence base 
for the clinical utility of genetics-based diagnostics.
Developing evidence to inform dosing algorithms for tests 
that reduce adverse events is made more complicated by the 
lack of timely biomarkers available to assess the efficacy of 
the reduced doses of treatment, particularly in oncology.50–52 
While there may be sufficient evidence to indicate that a 
pharmacogenetic marker is predictive of adverse events, 
pharmacogenetics-based evidence guiding the new dosage 
of a drug and the subsequent impact of altered doses of 
medicines on patients’ outcome is scarce and demonstrating 
clinical utility requires evidence linking the alternative dosing 
strategy with patient outcomes.43,44
Health status
The impact of an intervention on health status is the preferred 
outcome measure in economic evaluations.53 Methodological 
issues regarding the valuation of health outcomes for phar-
macogenetics, particularly the quality-adjustment (utility) 
component in QALYs, are similar to those faced by other 
health care  interventions. These issues tend to revolve around 
the preferred approach to use to value the quality-adjustment 
and associated preference weights.53 Discussions in the 
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general literature on the challenges of valuing the disutility of 
adverse events and the use of choice-based stated preference 
methods to derive utility values of adverse events based on 
study-specific descriptions of a health condition (vignettes)33 
are particularly relevant to the assessment of pharmacoge-
netic interventions that aim to reduce adverse events. The use 
of study-specific vignettes often leads to a lack of standard-
ization in the evidence base due to the assorted definitions 
and vignettes used to describe an adverse event of interest.33 
This can cause additional hurdles to the analyst, especially 
when choosing the utility value that is most suitable for use 
in an economic model. Despite this fact, questionnaires 
based on vignettes remain useful in assessing the utility of 
adverse events. A potential solution to guide the selection 
of the utility values obtained is to develop vignettes that are 
based on a clinical definition of an adverse event, instead of 
a study specific definition.33
Resource use and cost data
Similar to evaluations of other health care  interventions, cost 
data used in evaluations of pharmacogenetics should ideally 
be based on actual resource use of the patient population 
of interest, either observed within a clinical trial or based 
on observational data. Resource use data are subsequently 
combined with unit cost data to generate the relevant cost 
data, preferably published national unit costs.53
There are however two key components of costs associ-
ated with the use of a pharmacogenetic technology: 1) the 
short-run downstream costs consisting of the actual testing 
process, interpretation of the test results, and subsequent 
change in prescribing, and 2) the long-run downstream 
costs consisting of the economic impact due to the change 
in prescribing and subsequent changes to care pathways as 
well as patient outcomes. Due to the paucity of prospective 
studies, and challenges in designing and funding them,10,11,13 
there is generally limited actual resource use data of the 
patient population of interest to inform economic evaluations 
of pharmacogenetics.
There is also limited available information on published 
acquisition costs for the companion diagnostic component of 
a pharmacogenetic technology. Unlike medicines, where the 
costs are published as national price lists for the relevant juris-
dictions, there are no national price lists available for genet-
ics- and genomics-based diagnostic tests.54 Furthermore, 
there is likely to be a marked difference in the unit cost for 
pharmacogenetic tests developed by a laboratory compared 
with companion diagnostics that have been through a regu-
latory approval process and marketed as a standalone test. 
Large variations in the unit costs of these tests can affect the 
findings of an economic evaluation and increase uncertainty 
in the estimated relative cost-effectiveness of a test.
Uptake of pharmacogenetic tests
Potential variations in the uptake of pharmacogenetic 
tests and in the implementation of the test results within 
patients’ clinical pathways in economic evaluations are 
issues that are seldom considered. To date, the majority of 
economic evaluations have assumed perfect implementa-
tion of the test results and perfect uptake of a pharmaco-
genetic test.14,17 However, a UK-based pragmatic clinical 
trial (TARGET) assessing the use of TPMT genotyping to 
inform azathioprine dose selection and reduce the incidence 
of azathioprine-induced neutropenia37 illustrated how the 
results of a pharmacogenetic test are not always followed as 
intended. The trial found that although clinicians followed 
the trial’s pharmacogenetics-based dosing recommendation 
for patients with a heterozygous TPMT genotype by start-
ing azathioprine at a low dose, they did not comply to the 
dosing recommendation for patients with a wild-type TPMT 
genotype. Instead of immediately starting these patients on 
the standard maintenance dose, patients with a wild-type 
TPMT genotype were still prescribed a lower starting dose 
that is subsequently titrated upwards over time, similar to 
usual clinical practice. The authors37 suggested that this could 
be due to the implicit concern that TPMT genotyping does 
not predict other azathioprine-related adverse events. This 
concern is likely to apply to most pharmacogenetic inter-
ventions that aim to reduce adverse events, as genetics are 
only one of many factors influencing variability in adverse 
events profile. The economic evaluation based on the TAR-
GET trial subsequently concluded that TPMT genotyping 
potentially offers a less expensive alternative than current 
practice, but it may also have a small but negative effect on 
health status.55 This example illustrates the need for careful 
consideration when estimating the uptake of pharmacoge-
netics within clinical practice, particularly in model-based 
economic evaluations.
Current developments in the 
assessment of pharmacogenetics
Current developments to address the challenges of assess-
ing the cost-effectiveness of pharmacogenetic technologies 
revolve around two central issues that are interlinked: 
the need to adapt available evaluation methods and iden-
tifying who is responsible for generating evidence for 
pharmacogenetics.
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An iterative approach to evaluation
It has been said that the prospects for personalized medicine 
do not obviate the need for evaluation; they change the kind 
of evaluation that is needed.56 Current trends observed in 
the literature illustrate that this is already happening,10,11,13 
with most assessments of pharmacogenetics being model-
type evaluations in response to the scarcity of trial-based 
data for pharmacogenetics. The general paucity of outcome, 
health status, and cost data specific to pharmacogenetic 
interventions means that it may be necessary in the early 
developmental stages to design and populate relatively simple 
economic models as opposed to more complex models.16 An 
iterative approach could then be employed that systemati-
cally and explicitly considers the need for further evidence 
to reduce decision uncertainty,57 and is consistent with an 
approach to health technology assessment (HTA) known as 
constructive technology assessment.58 An iterative approach 
may enable decision-makers to prioritize both clinical and 
cost-effectiveness research and allow for timely decision-
making with regard to the use of companion diagnostics. 
Efforts to populate simple economic models in the presence 
of limited evidence may necessitate the use of nontraditional 
and alternative sources of data, including methodically docu-
mented and reported expert opinion.59 There are assorted 
elicitation methods relevant to economic modeling, such as 
the use of surveys60 or Delphi methods,61 to describe patient 
care pathways for the model structure and mathematical 
aggregation methods to populate model parameters.62,63 The 
iterative approach can be accompanied by value of informa-
tion (Vol) analysis to provide a quantitative estimate of the 
value of future research to reduce current uncertainty in the 
evidence used to populate model parameters.64
The need for methodological research
A review by Annemans et al16 presented ten issues that 
pose specific methodological challenges when design-
ing and conducting model-type economic evaluation 
of personalized medicine. The review16 emphasized 
the importance of issues relating to the correct framing 
of the research question, interpretation of test results, 
data collection of medical management options after 
obtaining test results, and expressing the value of tests.
A structured review of the literature by Buchanan et al17 
that considered methodological challenges for economic 
evaluations of genomic technologies identified similar issues 
to the review by Annemans et al.16 While these issues may 
also arise in evaluations of most types of health care inter-
ventions, it is the sheer quantity and range of challenges that 
makes it a unique challenge for assessing  pharmacogenetics.17 
The review by Buchanan et al17 concluded that while new 
methods may be needed to assess the cost-effectiveness 
of genomics, there is still insufficient evidence to justify 
alternative approaches. In view of this and the lack of con-
sensus on economic evaluation methods that can be used for 
pharmacogenetics, the authors recommend for analysts to 
conduct extensive and wide-ranging sensitivity analyses.17 
Such analyses may consider multiple perspectives, broader 
ranges, types of costs, and outcomes.17 The analyses could 
also incorporate various scenario and structural uncertainties, 
such as variations in the delivery models of pharmacogenetic 
services.17
However, while expanding scenario and sensitivity 
analyses is a potential solution for the assessment of phar-
macogenetics, this would result in a higher degree of uncer-
tainty of the findings. Variations in the methods used may 
also hinder the comparison of cost-effectiveness evidence 
between pharmacogenetic technologies, negating one of 
the main advantages of utilizing economic evaluations, 
particularly with the use of QALYs as an outcome measure 
in health care  decision-making. A review of the literature 
by Beaulieu et al65 noted a high degree of heterogeneity 
between studies assessing the same pharmacogenetic test 
and suggested a list of pharmacogenetic-specific parameters 
that should be consistently included in economic evaluation 
of pharmacogenetics, such as prevalence of the biomarker, 
outcome of genetics-based treatment as well as cost of 
genomic data collection and analysis. The concern that dif-
ferent methodological approaches may lead to conflicting 
adopting decisions17 also persists and in the long-term, it 
is still necessary to simultaneously focus on developing 
methods applicable to pharmacogenetics while ensuring 
policy makers are clear as to which evaluation methods are 
preferred to assist decision-making.
There is thus a need for realistic expectations regarding 
the standards66 and type of clinical evidence needed for 
reimbursement. To date, a common method employed is 
retrospective analyses of trial data.67 However, such analyses 
are only possible where data or samples from trials exist 
(such as from tissues of patients) and can then be analyzed 
retrospectively. Clinical information obtained prospectively 
is usually of a higher quality than retrospective data not least 
because it is not always feasible to conduct tests retrospec-
tively. In addition, trials need to be sufficiently large, and it 
should be noted that selection bias may occur where there 
is missing data. Potential alternative solutions may involve 
the use of novel trial designs, such as adaptive clinical 
Pharmacogenomics and Personalized Medicine 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
122
Shabaruddin et al
trials,68,69 evidence from observational studies, and clinical 
practice.45,66
Generating clinical evidence  
to populate models
The lack of relevant clinical data to populate model-based 
economic evaluations of pharmacogenetic tests is cited to be 
the main barrier to the introduction of personalized medicine 
into clinical practice.70,71 Adaptive clinical trials have been 
suggested as a means of speeding up the development of 
new interventions by reducing the size of the clinical trial 
by enabling a flexible trial design.68,69 In general, adaptive 
clinical trial methods are accepted in the exploratory stages 
of clinical trials.72
The most widely understood adaptive trial design is 
the group sequential design that allows stopping a trial 
early if it becomes clear that a treatment is superior or 
inferior; such a design is accepted as a valid trial design 
by some regulators, such as the United States Food and 
Drug Administration (FDA).72 However, many other novel 
approaches also exist, such as adaptive randomization.68,69 
When used properly, it is argued that adaptive clinical tri-
als can result in a more efficient treatment development 
process, and an increased chance of correctly answering 
the clinical question of interest. However, improper adap-
tations can lead to biased studies although it is argued 
that logistical issues and regulatory concerns, rather than 
statistical issues, currently limit the use of such trials.68,69 
For example, such trials require a different way of think-
ing about the structure and conduct of Data and Safety 
Monitoring Boards.68,69
There is also a movement toward using observational 
studies rather than randomized trials. The Clinical Phar-
macogenetics Implementation Consortium (CPIC), based 
in the United States, develops peer reviewed guidelines on 
how to use available pharmacogenetic test results in order to 
optimize treatment based on evidence derived from patients’ 
medical records. However, the CPIC does not address the 
crucial question of whether a pharmacogenetic test should or 
should not be ordered.45 Currently, there are approximately 
30 gene-drug pairs with CPIC dosing guidelines.73 The selec-
tion of gene-drug pairs is based on several factors, including 
surveys of experts in the relevant fields, the availability of 
strong evidence linking drug response or adverse events 
with genetic variations, clinically actionable prescribing 
recommendations, alternative therapeutic strategies based 
on pharmacogenetics, and the actual pharmacogenetic tests 
for use within clinical practice.45
While the development of CPIC guidelines is a positive 
step toward moving pharmacogenetics-based individualized 
treatment into routine clinical practice, it may be argued 
that they also imply that existing challenges in assessing 
pharmacogenetics are insurmountable. This is because these 
guidelines bypass the traditional data requirements needed 
to support the use of a new intervention and move straight to 
producing recommendations for its use in clinical practice. 
Even with the implementation of CPIC guidelines, there 
may still be insufficient evidence on the clinical and cost-
effectiveness of interventions upon which policy makers can 
make reimbursement decisions.74 The widespread use of any 
health care  intervention depends on its availability within 
clinical practice. This is typically linked to reimbursement 
decisions by health care  payers. Hence, the CPIC guidelines 
offer only an alternative in the unusual circumstances where 
a test’s use is widespread in practice despite lacking a robust 
evidence base for its effectiveness. This highlights a pressing 
need to boost the generation of a robust evidence base for 
pharmacogenetics by alternative means that can satisfy the 
demands of health care  payers.
Responsibility for generating  
evidence for pharmacogenetics
The derivation of an economic evidence base sufficient to 
inform health care  resource allocation decision has a clear 
opportunity cost in terms of alternative uses of a research 
budget.75 It is necessary to be clear who is responsible for 
generating the evidence required. For medicines, there are 
clear regulatory and reimbursement systems in place and 
pharmaceutical companies are aware that they are expected 
to derive good quality evidence from RCTs to comply with 
the requirements set by regulators, reimbursement agen-
cies, or national bodies that inform health care  funding 
decisions.76–79 In contrast, there is substantial uncertainty 
about the level of evidence considered to be sufficient to 
support the use of pharmacogenetic technologies and in most 
instances there is also uncertainty as to who is responsible for 
producing such evidence, particularly the types of evidence 
on cost-effectiveness that are needed by health care  payers 
and policy makers.80
The task of generating a robust evidence base for phar-
macogenetics need not be shouldered by a single sector and 
can be shared with pharmaceutical companies, which are now 
increasingly aware of the advantages of developing tests for 
somatic mutations alongside drug development. A 2007 sur-
vey of 16 of the top 20 pharmaceutical companies conducted 
by McKinsey indicated that on average, up to 50% of drugs 
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in development have an associated biomarker program,81 
a finding also found from a separate survey conducted by the 
Tufts Center for the Study of Drug Development.82 However, 
the findings by McKinsey also indicated that fewer than 10% 
of drugs would be launched with a companion diagnostic 
over the next 5–10 years.81 The authors suggested that this 
finding largely reflected the benefits and risks faced by phar-
maceutical companies when adopting a companion  diagnostic 
strategy.81 Potential benefits cited included increased pro-
ductivity by decreasing trial sizes, reducing attrition, or 
increasing speed to market, as well as enhancing commercial 
performance by boosting market share or supporting higher 
drug prices.81 Deverka et al83 described how the pharmaceuti-
cal company (Roche) that manufactures trastuzumab found 
that introducing HER2 testing into its pivotal clinical trial 
reduced development costs (by an estimated US$35 million), 
trial size (from 2,200 to 470 patients), and the time it took to 
bring the product to the market (from a projected 10 years to 
1.6 years). However, these observations83 from one specific 
example may not be generalizable to other scenarios. There 
are potential risks to having an associated personalized 
medicine program,81 including delays in study development, 
increased costs, and a decrease in market share caused by 
the identification of a more specific patient population based 
on pharmacogenetics.
The generation of an evidence base to inform the reim-
bursement of pharmacogenetic technologies that involve a 
companion diagnostic to identify germline variations, such 
as variations in drug metabolizing enzymes, is likely to be 
more problematic than for somatic variations. This is because 
the majority of such pharmacogenetic tests are used to target 
existing drugs that have been on the market for a number of 
years and as such, are off patent.73 Another issue is that many 
of the pharmacogenetic tests for germline variations can be 
used to inform prescribing decisions of multiple drugs, such 
as CYP2D6 genotyping.30,31 In such situations, it is not clear 
who might be responsible (or indeed have the incentive) for 
generating the required evidence base. The implications of 
the current paucity of data are showcased by the examples 
of two HTAs that aimed to conduct model-based economic 
evaluations of CYP2D6 testing for tamoxifen84 and CYP450 
testing of anti-psychotic medications.25 Both HTAs were 
unable to produce an assessment of cost-effectiveness due 
to a lack of evidence for clinical effectiveness (which mainly 
comprised retrospective studies) and consequently, cost-
effectiveness.
Current policies of most regulatory and reimbursement 
systems are not resulting in the compilation of sufficient 
evidence on the value of identifying responders or patients 
likely to experience adverse events.66 This situation points to 
a need to incentivize the generation of evidence for technolo-
gies used to personalize medicine.66,85,86 Previous suggestions 
for economic incentives for evidence generation include 
value-based price flexibility, intellectual property protec-
tion for the evidence generated, realistic expectations for 
the standards of evidence needed, and public investment to 
complement the effort of payers and manufacturers.66 Public 
funding bodies, such as the Medical Research Council in 
the UK,87 have addressed the lack of evidence by setting up 
extensive funding streams for stratified medicine, looking 
specifically at existing medicines. Research funding streams 
such as these should change the future landscape in terms 
of the available evidence to support personalized medicine. 
This increase in available funding must be matched with an 
associated improvement in the design and conduct of studies 
to generate an evidence base sufficient to inform whether 
scarce health care  resources should be diverted toward 
genetics- and genomics-based technologies.
Concluding remarks
Identifying and quantifying the incremental costs and 
benefits of technologies used to personalize medicine 
using robust economic evaluations has a key role in the 
context of health care  systems needing to decide how best 
to allocate scarce health care  resources. The discipline of 
health economics provides methods of economic evaluation 
to generate evidence of the relative cost-effectiveness of 
genetics and genomics-based technologies compared with 
current clinical practice. As these technologies continue 
to develop, and become more complex (such as with an 
increasing number of gene variations tested for at a time 
and able to inform prescribing of multiple drugs), there is 
a need to constantly develop new evaluative methods and 
evidence of clinical and cost-effectiveness that is sufficient 
for timely and informed resource allocation decision-
making. However, as the technologies become increasingly 
complex, the derivation of such evidence also becomes 
more complex. In this paper, we have highlighted some of 
the main challenges and presented current developments in 
addressing these issues.
Decision-makers need to recognize that the development 
of evidence has substantial implications for the effective use 
of resources and hence there is a need for economic incen-
tives to support the generation of a robust evidence base for 
personalized medicine. Resolving methodological issues 
relating to the derivation of evidence for, and assessment of, 
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genetics and genomics-based technologies and identifying 
who is responsible for generating evidence are integral to sup-
port the reimbursement of genetics and genomics-based tests 
by health care  payers and thus move personalized medicine 
from bench to bedside.
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